Ligand Pharmaceuticals Incorporated (Nasdaq: LGND), a San Diego, CA-based biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines, acquired Apeiron Biologics AG, a Vienna, Austria-based private biopharmaceutical company, for $100M.
The acquisition will provide Ligand with the royalty rights to QARZIBA®, a commercial oncology drug marketed in 35 countries by global pharmaceutical company Recordati S.p.A.
Led by CEO Peter Llewellyn-Davies, Apeiron is a private biopharmaceutical company co-developing QARZIBA for the treatment of high-risk neuroblastoma in patients aged 12 months and above. It was approved by the European Medicines Agency in 2017 and is commercially available today in more than 35 countries.
Led by CEO Todd Davis, Ligand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Its business model focuses on funding programs in mid- to late-stage drug development in return for economic rights, purchasing royalty rights in development stage or commercial biopharmaceutical products and licensing its technology to help partners discover and develop medicines.
Ligand has established multiple alliances, licenses and other business relationships with biopharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International.
FinSMEs
08/07/2024